ProCE Banner Activity

Pooled Analysis of Impact of TP53 Mutations on Efficacy of Venetoclax + Azacitidine in Patients With AML and Poor-Risk Cytogenetics

Slideset Download
Conference Coverage
In older/unfit patients with AML and poor-risk cytogenetics, frontline treatment with venetoclax plus azacitidine improved DoR and OS vs Aza in wild-type but not mutated TP53.

Released: December 17, 2021

Expiration: December 16, 2022

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Daiichi Sankyo, Inc.


Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation